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The definition of a biomarker provided by the World Health Organization is any substance, structure, or process that 
can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. Currently, the 
lack of prognosis and progression markers for chronic Chagas disease has posed limitations for testing new drugs to treat 
this neglected disease. Several molecules and techniques to detect biomarkers in Trypanosoma cruzi-infected patients 
have been proposed to assess whether specific treatment with benznidazole or nifurtimox is effective. Isolated proteins or 
protein groups from different T. cruzi stages and parasite-derived glycoproteins and synthetic neoglycoconjugates have 
been demonstrated to be useful for this purpose, as have nucleic acid amplification techniques. The amplification of T. cru-
zi DNA using the real-time polymerase chain reaction method is the leading test for assessing responses to treatment in a 
short period of time. Biochemical biomarkers have been tested early after specific treatment. Cytokines and surface mark-
ers represent promising molecules for the characterisation of host cellular responses, but need to be further assessed.
Key words: biological marker - Chagas disease - Trypanosoma cruzi - therapeutic response - parasite marker - host markers
doi: 10.1590/0074-02760140435
Financial support: CRESIB and IPBLN research members were par-
tially supported by the RICET (RD12/0018/0010, RD12/0018/0021),
M-JP and JG received research funds from AGAUR (2014SGR26) 
and Fundación Mundo Sano, M-CT and M-CL were supported 
by Plan Nacional de I+D+I (MINECO-Spain) (SAF2012-35777, 
SAF2013-48527-R and FEDER), ICA was partially supported by 
NIMHD/NIH (2G12MD007592).
+ Corresponding author: mariajesus.pinazo@cresib.cat
Received 17 November 2014
Accepted 25 February 2015
The definition of a biological marker (and its portman-
teau, “biomarker”) is still under discussion. A biomarker 
is a medical sign that can be measured accurately and 
reproducibly (Strimbu & Tavel 2010). The International 
Programme on Chemical Safety led by the World Health 
Organization (WHO 1993) has defined a biomarker as 
“any substance, structure or process that can be mea-
sured in the body or its products and influence or predict 
the incidence or outcome of disease” (WHO 2001). A 
broader definition by the same working group included 
not only the incidence and outcome of disease, but also 
the effects of treatments, interventions and environ-
mental exposures. Although they are commonly used in 
clinical research (even as primary endpoints), laboratory-
measured biomarkers in clinical research are still being 
developed and their use for the diagnosis and evaluation 
of responses for some diseases is still in progress.
Currently, there is a lack of validated early markers 
for therapeutic responses to chronic Chagas disease. The 
gold standard for evaluating treatment efficacy is the 
seroconversion of conventional serological tests, which 
may take years to decades to assess (Viotti et al. 2006, 
Fabbro et al. 2007). Currently, biomarkers are potentially 
useful for two purposes: to evaluate the efficacy of cur-
rent drugs in a short period of time, raising the possibil-
ity of precisely informing patients about their therapeu-
tic progress and to provide valid tools for use in clinical 
trials with new drugs. The use of biomarkers will allow 
the improvement of therapeutic options for people who 
suffer from this neglected disease.
Recently, several prognosis and progression markers 
for T. cruzi infection have been developed or discovered, 
but only a few of them have been evaluated after specific 
treatment and using appropriately designed studies. Two 
systematic reviews were conducted over the last year to 
evaluate the following criteria: (i) the usefulness of the 
various types of blood-derived biomarkers that are cur-
rently under study to predict the progression of Chagas 
disease in patients with the indeterminate form, to assess 
the efficacy of antiparasitic drugs and to identify early 
cardiac or gastrointestinal damage (Requena-Méndez 
et al. 2013) and (ii) the therapeutic use of potential bio-
markers and their disease stage-specific characteristics 
(Pinazo et al. 2014). Both reviews were based on current 
evidence and focused on the quality of biomarker stud-
ies. Additionally, the second review (Pinazo et al. 2014) 
established that molecules should fulfill several specific 
quality criteria for evaluating responses to treatment for 
chronic Chagas disease. A target product profile was 
developed based on the available evidence concerning 
biomarkers and the experience of an expert group on the 
field (New Tools for Diagnosing and Evaluating Chagas 
Disease Patients Working Group).
The conclusion of the reviews revealed that even if 
there is heterogeneity in the data concerning biomark-
ers studied by different groups, certain biomarkers have 
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TABLE
Summary of major biomarkers described in the review 
Parasite biomarkers
Parasite molecules
rTc24 Krautz et al. (1995)
tGPI-mucins (F2, F2/3 or AT antigen) Almeida et al. (1993),
de Andrade et al. (1996),
Andrade et al. (2004)
Complement regulatory protein Meira et al. (2004)
F-IV fraction and EXO Moretti et al. (1998)
F29 Sosa-Estani et al. (1998), 
Fabbro et al. (2013)
Ag13 Sanchez-Negrette et al. (2008)
P2β Fabbro et al. (2011)
Recombinant proteins set 
(multiplex)
Cooley et al. (2008), 
Viotti et al. (2011)
KMP11, H70, PFR2, Tgp63 Fernández-Villegas et al. (2011, 2014)
Parasite DNA/RNA amplification techniques
Polymerase chain reaction techniques Britto et al. (1999, 2001), 
Fernandes et al. (2009), 
de Lana et al. (2009), 
Gomes at al. (2009), 
Murcia et al. (2010), 
Pérez-Ayala et al. (2011), 
Aguiar et al. (2012), 
Machado-de-Assis et al. (2012)
Aptamers L44 Nagarkatti at al. (2012, 2014)
Host response/damage biomarkers
Immunological markers
TSKb20 Bustamante et al. (2008),
Costa et al. (2009)
CD62L, CD127 Bustamante et al. (2014)
CD27, CD28 Appay et al. (2008)
TEM CD45RA+ CCR7 Albareda et al. (2006)
CD40L Chamekh et al. (2005), 
Habib et al. (2007) 
Interferon-γ Romanha et al. (2002), 
Ferraz et al. (2007), 
Laucella et al. (2009), 
Poveda et al. (2014), 
Sousa et al. (2014) 
Interleukin (IL)-10 Sousa et al. (2014)
IL-17 Kolls and Lindén (2004), 
Miyazaki et al. (2010), 
Magalhães et al. (2013), 
Costa et al. (2009)
CCL2/monocyte chemotactic protein-1 Paiva et al. (2009), 
Tuñón et al. (2014) 
Macrophage inflammatory protein-1α/CCL3 Roffê et al. (2010), 
Falcão et al. (2002)
Ab amastigotes, trypomastigotes, epimastigotes Alessio et al. (2014)
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been shown to be effective in assessing responses to spe-
cific treatment with benznidazole (BZ) and nifurtimox 
(NFX) in different stages of Chagas disease. Biomark-
ers for evaluating responses to specific treatments for 
people suffering from chronic Chagas disease can be 
classified into two groups: parasite biomarkers and host 
response/damage biomarkers.
The aim of this article is to provide an update on 
advances in the research of several of these molecules. 
Table summarises the major biomarkers described in 
this report and the related references. However, this re-
view will be mainly focused on parasite-derived protein 
and DNA biomarkers and host-derived biochemical and 
immunological biomarkers. Due to its complexity, gly-
coconjugate biomarkers that effectively measure lytic, 
protective anti-α-galactosyl antibody levels have been 
extensively discussed elsewhere (Almeida 2014).
Parasite biomarkers 
Parasite biomarkers include several proteins and 
glycoproteins  isolated from the parasite (i.e., the F29 
protein) (Fabbro et al. 2013), as well as protein groups, 
recombinant proteins, proteins purified from different 
forms of the parasite (Cooley et al. 2008, Fernández-
Villegas et al. 2011) and parasite-derived glycoproteins 
and synthetic neoglycoconjugates (Almeida et al. 1993, 
1994, Ashmus et al. 2013). Nucleic acid amplification 
techniques, such as real-time polymerase chain reaction 
(PCR) or the use of RNA ligands (aptamers) (Nagarkatti 
et al. 2014), are also included in this group.
Parasite proteins - Current tests for the diagnosis of 
Trypanosoma cruzi infection are mainly reliant on con-
ventional serological techniques that have high sensitivity 
and specificity (Britto et al. 2001, Cançado 2002, Coura 
& de Castro 2002). However, these methods of diagnosis 
are not effective in determining the evolution of chronic 
disease in Chagas patients after treatment. Consequently, 
there are no early markers to detect recovery after treat-
ment, making both the clinical follow-up of the affected 
patients and clinical trials with new drugs difficult. In this 
context, several systems have been tested as markers of 
therapeutic efficacy with relative success in prospective 
and retrospective trials. These assays are based on the de-
tection of specific antibodies against parasite antigens.
In one retrospective study, a 24-kDa recombinant 
protein from T. cruzi (rTc24) was evaluated by ELISA 
and western blot tests. The study pursued the identifi-
cation of treated chagasic patients who were considered 
uncured or cured based on a positive or persistent nega-
tive lytic antibody test (by complement-mediated lysis, 
CoML), respectively (Krautz et al. 1995). Forty sera sam-
ples from treated patients who were considered uncured 
because they presented a positive CoML test reacted with 
rTc24. Fourteen of these samples had negative haemoc-
ultures. Moreover, 22 out of 28 (79%) sera samples from 
treated patients with negative CoML and haemoculture 
tests, but with a positive result in the indirect immun-
ofluorescence test, showed no reactivity against rTc24. 
The authors concluded that the rTc24 molecule could be 
used to assess the cure of treated Chagas patients.
A similar retrospective study evaluated an ELISA 
based on the recombinant T. cruzi complement regula-
tory protein (rCRP) as a method for determining parasite 
clearance. The study included sera from 31 patients col-
lected before and after treatment (Meira et al. 2004). The 
results were compared to those obtained by other meth-
ods, such as CoML, conventional serology and haemoc-
ulture. The results showed that the percentage of patient 
samples that were positive by rCRP ELISA was reduced 
from 100-70.3%, 62.5%, 71.4% and 33.4% in the first, sec-
ond, third and fourth years after treatment, respectively. 
The authors also showed that the percentage of positive 
samples by CoML was reduced to 85.2%, 81.2%, 71.4% 
and 33.4% during the same period of time, demonstrating 
the same tendency in the reduction of positive samples.
The serological reactivity of 42 chronic chagasic pa-
tients treated with NFX or BZ for two-20 years and 42 
untreated patients (Moretti et al. 1998) against the F105 
antigen, the F-III and F-IV fractions from T. cruzi extracts 
and the exo-antigens from trypomastigote-infected mice 
(EXO) was analysed by ELISA. The results showed a sig-
nificant decrease in serologic reactivity against the F-IV 
fraction and EXO antigen in 64% and 44% of treated vs. 
33% and 8% of untreated patients, respectively. No differ-
ences in reactivity against the F105 antigen and F-III frac-




[troponin I, T, atrial natriuretic peptide, 
brain natriuretic peptide (BNP) proBNP]
Puyó et al. (2002, 2005), 
Ribeiro et al. (2003), 
Heringer-Walther et al. (2005), 
Machado et al. (2005), 
Moreira et al. (2008), 
García-Alvarez et al. (2010), 
Lima-Costa et al. (2010) 
Selenium Rivera et al. (2002)
Apolipoprotein A1 and fragments (F) Santamaria et al. (2014) 
Endogenous thrombin potential, F1+2 Pinazo et al. (2011)
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Purified trypomastigote-derived glycosylphosphati-
dylinositol-anchored mucin glycoproteins (tGPI-mucins), 
also known as F2, F2/3 or AT antigen, were previously 
used in a chemiluminescent ELISA (AT CL-ELISA) to 
measure lytic anti-α-Gal antibody titres to confirm the 
efficacy of BZ treatment of chronically infected chil-
dren and adolescents from an endemic area in a placebo-
controlled randomised trial (de Andrade et al. 1996). Al-
though all conventional serology tests remained positive 
after a three-year observation period, 58% of 64 children 
were considered cured according to the AT CL-ELISA. 
In a follow-up of that study, Andrade et al. (2004) con-
firmed successful BZ chemotherapy in ~65% and ~85% 
patients by intention-to treat and by per protocol analy-
sis, respectively, as measured by seroconversion using 
AT CL-ELISA six years after the end of treatment. In 
a subsequent study, reactivity against the recombinant 
T. cruzi flagellar calcium-binding protein (F29) was 
analysed by ELISA for use as a short-term monitoring 
method to test the efficacy of BZ in children in the inde-
terminate phase of Chagas disease. The results from this 
double-blind, randomised, clinical field trial study indi-
cated that 35.2% and 62.1% of the 44 BZ-treated children 
were seronegative for the F29 antigen six and 48 months 
post-treatment, respectively (Sosa-Estani et al. 1998). Re-
cently, the ELISA-F29 test was also used to compare the 
time at which negative seroconversion against the F29 an-
tigen was detected vs. conventional serology. The study 
included 29 patients who received NFX or BZ treatment 
and 37 untreated subjects (Fabbro et al. 2013). The data 
obtained showed that seroconversion was detected sig-
nificantly earlier using the ELISA-F29 test compared to 
conventional serology, with values of 14.5 ± 5.7 and 22 ± 
4.9 years, respectively. Likewise, regression in antibody 
levels against different recombinant molecules (Ag1, 
Ag2, Ag13, Ag30, Ag36 and SAPA antigens) was used to 
detect early markers of treatment effectiveness (Sanchez-
Negrette et al. 2008). The specific-antigen antibody lev-
els against these molecules were monitored in sera from 
18 adult patients after three years post-treatment. Before 
treatment, most of the patients had specific reactivity 
against these antigens; after treatment, the specific reac-
tivity against some of these antigens was reduced in 50% 
(9/18) of the patients. The best results for this technique 
as a marker of treatment efficacy were obtained for Ag13 
due to the occurrence of negative seroconversion in six 
out of the nine patients who presented specific antibodies 
against this antigen before treatment.
The dynamics of reactivity against the T. cruzi ribosom-
al protein (P2β) were evaluated in a retrospective study us-
ing sera from treated and untreated chronic Chagas disease 
patients who were followed for more than 20 years. The ob-
tained data showed that the levels of antibodies against P2β 
decreased from their initial values in treated asymptomatic 
patients, but did not decrease in asymptomatic or untreated 
cardiomyopathy patients (Fabbro et al. 2011).
In addition to the decrease in antibody titres, seron-
egative conversion was measured in 53 BZ-treated and 
89 untreated chronic patients with an average follow-up 
time of 36 months using conventional serological assays 
(immunoassay, indirect fluorescent immunoassay and 
ELISA) and a set of 16 T. cruzi proteins incorporated into 
a multiplex bead array (Cooley et al. 2008). A decrease in 
antibody titres against T. cruzi was detected by conven-
tional serology tests in 64% of treated patients vs. 21% 
of untreated patients and seronegative conversion against 
the set of proteins was detected in 40% of treated vs. 7% 
of untreated patients. Moreover, a strong correlation be-
tween the results from conventional serological tests and 
the multiplex assay was detected (Viotti et al. 2011).
A prospective study performed using sera from 46 
adult chronic Chagas disease patients and 22 healthy do-
nors showed that the set comprising four recombinant pro-
teins (KMP11-H70-PFR2-Tgp63) could serve as a useful 
tool for monitoring the effectiveness of Chagas disease 
treatment (Fernández-Villegas et al. 2011). Regardless of 
the phase of Chagas disease, the sera from chagasic pa-
tients reacted against the above mentioned antigens with 
statistical significance relative to the recognition level 
of sera from healthy donors, patients with autoimmune 
diseases or patients suffering from other related infec-
tious diseases, such as tuberculosis, leprosy or malaria. 
Shortly after BZ treatment, a drop in reactivity against 
three of these antigens (KMP11, PFR2 and HSP70) was 
detected in an antigen-specific manner. Thus, a statisti-
cally significant decrease in reactivity against KMP11 
occurred six months post-treatment in 74% of patients, a 
drop in reactivity against PFR2 occurred at nine months 
post-treatment in 74% of patients and a drop in reactivity 
against HSP70 occurred at nine months post-treatment 
in 71% of Chagas disease patients. The drop in reactivity 
remained constant or continued to decrease during the 
post-treatment follow-up period (24 months). A further 
decrease in reactivity was detected in 67%, 50% and 34% 
of patients for KMP11, PFR2 and HSP70, respectively. 
However, no statistically significant drop in reactivity 
was observed against total soluble T. cruzi proteins.
The KMP11-H70-PFR2-Tgp63 serological biomarker 
was recently employed in a blind post-treatment follow-
up of twin brothers congenitally infected with the same T. 
cruzi strain (Fernández-Villegas et al. 2014). Remarkably, 
a drop in reactivity against these proteins was correlated 
with treatment success in brother I. However, no modifi-
cation in the antibody titre against these proteins (which 
would have allowed a treatment interruption) was detected 
in brother II. A drop in reactivity against these molecules 
that was correlated to treatment success was observed 45 
days after administration of the second treatment.
Parasite DNA/RNA amplification techniques - Am-
plification of T. cruzi DNA is currently the leader test 
for assessing the response to treatment in a short period 
of time in patients with chronic T. cruzi infection. To 
date, this method has been mainly used in clinical trials 
for this purpose.
PCR techniques have been mainly used to assess 
treatment failure when a positive result was obtained, to 
diagnosis patients in the acute stage of the disease and 
for the early detection of reactivation of the disease in 
organ transplant patients. Compared with other parasi-
tological diagnostic methods (i.e., haemoculture and xe-
nodiagnoses), the sensitivity obtained by the PCR tech-
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nique is higher for patient treatment follow-up (Britto 
et al. 1999, 2001, de Lana et al. 2009, Fernandes et al. 
2009). Currently, due to improvements in PCR tech-
niques the possibility of performing quantitative PCR 
in real time quantitative reverse transcription-PCR has 
provided more specificity for these tests.
However, blood parasitaemia fluctuates during the 
chronic phase of infection and may be below the PCR de-
tection level, especially during the long period of follow-
up after trypanocidal treatment (Gomes et al. 2009, Mur-
cia et al. 2010, Pérez-Ayala et al. 2011). Several studies 
have used this technique, which has greatly improved the 
detection of treatment failure (85-89% of patients) (Britto 
et al. 1999, de Lana et al. 2009, Fernandes et al. 2009). 
However, a negative PCR result does not guarantee a 
parasitological cure or a response to a specific treatment. 
Nevertheless, PCR-negative conversion was achieved in 
some studies in a variable proportion of treated patients 
(Britto et al. 2001, Murcia et al. 2010, Pérez-Ayala et al. 
2011, Aguiar et al. 2012, Machado-de-Assis et al. 2012) 
in a manner that did not always correlate with negative 
seroconversion (Britto et al. 1995, Lacunza et al. 2006, 
Solari et al. 2001, Fernandes et al. 2009, Murcia et al. 
2010, Pérez-Ayala et al. 2011, Aguiar et al. 2012, Macha-
do-de-Assis et al. 2013). Thus, obtaining several samples 
from each patient at different intervals to increase the 
probability of detecting T. cruzi DNA in blood samples is 
recommended to increase the sensitivity of the PCR test.
Although parasite DNA amplification techniques 
provide a more rapid and sensitive test and could avoid 
very demanding long-term patient follow-up, this tech-
nique is not available in regular health care centres.
Short RNA ligands called aptamers have been recent-
ly developed as potential biomarkers that could be used 
to test the response to specific treatments in chronic Cha-
gas disease patients (Nagarkatti et al. 2012, 2014). These 
molecules have not yet been evaluated in humans, but 
have been used as diagnostic tests of both the acute and 
chronic stages of the disease in murine models. Aptam-
ers generated against T. cruzi excreted/secreted antigens 
(TESA) were purified from in vitro culture supernatants 
of infected host cells and used as specific ligands in en-
zyme-linked aptamer assays. Aptamer L44 showed sig-
nificant and specific binding to both TESA and a T. cruzi 
trypomastigote extract, but not to host proteins, proteins 
from Leishmania donovani (a related trypanosomatid 
parasite) or samples from noninfected mice.
Although they are still in an early stage of develop-
ment and further investigations should be performed, 
aptamers have a great potential for the evaluation of 
treatment efficacy and possibly a parasitological cure in 
human clinical trials.
Host response/damage biomarkers 
Biochemical biomarkers such apolipoprotein (APO) 
and fibronectin fragments (Santamaria et al. 2014) and 
hypercoagulability markers (Pinazo et al. 2011) have 
been tested early after specific treatments in patients in 
different stages of Chagas disease. Cytokines and sur-
face markers are promising molecules that can be used 
to characterise host cellular responses, but their use in 
gauging the response to treatment during T. cruzi infec-
tion needs to be further assessed.
Immunological markers of treatment efficacy - The 
development of markers to measure therapeutic responses 
in T. cruzi infected patients is currently the subject of in-
tense research. Drug discovery and the development of 
improved therapies for Chagas disease rely on the abil-
ity of assays to determine treatment outcomes. However, 
monitoring treatment efficacy in individuals infected with 
T. cruzi is still a significant hindrance. The major compli-
cation is associated with the fact that the parasite loads in 
chronically infected subjects (the main population in need 
of trypanocidal treatment) are controlled at extremely low 
levels. This situation has forced the need for an essential 
amplification step (blood culture or DNA isolation from 
the parasite) for the detection of parasites in patients who 
suffer from the chronic form of the disease (Bustamante 
& Tarleton 2011, Gilber et al. 2013, Muñoz et al. 2013).
Based on this complex scenario, the development of 
biomarkers to measure the treatment efficacy of Chagas 
disease is an imperative need in cases where the fail-
ure to detect T. cruzi is the most common result. Re-
cently, work on animal models has generated a widely 
accepted endpoint immunosuppression procedure for 
the assessment of cure following drug treatment (Busta-
mante et al. 2008, 2014, Canavari et al. 2010, Villalta 
et al. 2013). Using this system, the generation of anti-T. 
cruzi T cell responses based on the detection of major 
histocompatibility complex (MHC)-peptide tetramers 
that are uniquely specific for CD8+T cells recognising a 
transialidase peptide (TSKb20) were monitored as bio-
markers of treatment success (Bustamante et al. 2008, 
2014). Drug-cured mice showed a lower frequency of T. 
cruzi-specific CD8+ T cells and an increased number of 
memory T cells displaying a central memory phenotype 
(TCM) compared to their untreated counterparts (Busta-
mante et al. 2008). TCM cells as well as T effector mem-
ory cells (TEM) can be distinguished by their patterns of 
surface molecule expression. These molecules include 
the L-selectin receptor CD62L, which is essential for 
the ability of lymphocytes to traverse high endothelial 
venules and enter lymph nodes and the interleukin (IL)-7 
receptor alpha (CD127), which is involved in the homeo-
static maintenance of memory T cells. TCM cells general-
ly express both of these receptors, whereas TEM cells ex-
press neither (Sallusto et al. 1999, 2004). Therefore, the 
phenotype of T. cruzi-specific CD8+ T cells can be used 
as a potential marker for the determination of treatment 
efficacy and cure. Interestingly, conversion of T. cruzi-
specific CD8+ T cells from the largely TEM phenotype 
(CD62Llo, CD127lo) characteristic observed in persistent 
infection to a majority TCM cell population (CD62L
hi, 
CD127hi) has been observed when a cure is established 
with different treatment protocols, such as the combina-
tion of the anti-fungal posaconazole with BZ and the use 
of intermittent regimens (Bustamante et al. 2014).
Although an immunosuppression assay cannot be 
performed in humans for obvious ethical reasons, an ac-
cidental validation of this finding was recently reported 
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in an immunosuppressed patient with systemic lupus 
erythematosus who was treated with trypanocidal ther-
apy (posaconazole) to clear the infection (Pinazo et al. 
2010). Nonetheless, the tracking and phenotyping of T. 
cruzi-specific T cells in humans are complicated by their 
low frequency and largely unknown antigen specificity 
(Laucella et al. 2004, Alvarez et al. 2008). The frequency 
of peripheral interferon (IFN)-γ-producing T cells spe-
cific for T. cruzi declined in BZ-treated individuals 12 
months after follow-up; these cells subsequently became 
undetectable in a substantial proportion of the treated 
subjects (Laucella et al. 2009). In a previous work (Ap-
pay et al. 2008), a linear model of T cell differentiation 
based on the expression of the T cell surface markers 
CD27 and CD28 was proposed. In this model, CD27+ 
CD28+ T cells were defined as “early” differentiated 
memory CD8+ T cells, as opposed to the CD27- CD28- 
T cells considered to be “late” or “fully” differentiated 
memory CD8+ T cells. Using this model of differentia-
tion, Albareda et al. (2006) found that the frequency of 
early-differentiated CD8+ CD27+ CD28+ T cells in the 
entire CD8+ T cell memory compartment in T. cruzi in-
fected subjects decreased as the disease become more 
severe, while the proportion of fully differentiated mem-
ory (CD27- CD28-) CD8+ T cells increased. Addition-
ally, they also reported a significant increase in the total 
effector memory CD8+ T cell (TEM CD45RA+ CCR7-) 
population in T. cruzi infected subjects with mild heart 
disease compared with uninfected controls. However, 
whether the early-differentiated CD8+ T cells (CD27+ 
CD28+) that decreased in the more severe clinical picture 
will increase after trypanocidal treatment and whether 
this T cell subset can be used as a surrogate marker for 
treatment success remain to be explored.
CD40L (CD154) is a T cell marker that has been re-
ported to have prognostic value in some parasitic infec-
tions. CD40L, a member of the tumour necrosis factor su-
perfamily of molecules, is primarily expressed on activated 
T cells and can also be found in a soluble form (sCD40L). 
CD40L plays a role as a co-stimulatory molecule and in-
duces activation in antigen presenting cells (APCs) in asso-
ciation with T cell receptor stimulation by MHC molecules 
on the APC (van Kooten & Banchereau 2000). A previ-
ous work proposed that CD40L played a significant role 
in the control of T. cruzi infection in mice (Chamekh et al. 
2005, Habib et al. 2007). High levels of sCD40L in serum 
have been associated with favourable clinical evolution in 
human visceral leishmaniasis, suggesting a potential use 
of this marker for the prognosis of this disease and other 
related diseases (de Oliveira et al. 2013). However, the use 
of CD40L as a clinical marker for treatment efficacy in T. 
cruzi infection remains to be explored.
Cytokine profiles have been proposed as potential 
biomarkers of disease progression for some infectious 
diseases (i.e., malaria and human immunodeficiency vi-
rus) (Armah et al. 2007, Boulware et al. 2010, Erdman et 
al. 2011). Cytokines modulate the balance between the 
humoral and cell-based immune responses and play a 
pivotal role in the control of T. cruzi infection (Savino 
et al. 2007). The balance between the pro-inflammatory 
[T-helper (Th)1 immune response] and antiinflammatory 
(Th2 immune response) cytokines has been suggested to 
be critical in the development of the chronic phase of T. 
cruzi infection (D’Ávila et al. 2009, Dutra et al. 2009).
IFN-γ is one the main cytokines that regulate Th1 
immune responses. It is critical for innate and adaptive 
immunity against infection by viral and intracellular 
pathogens (Schoenborn & Wilson 2007). IFN-γ is essen-
tial for the control of T. cruzi infection and mediating a 
parasitological cure in experimental models (Romanha 
et al. 2002, Ferraz et al. 2007).
In human infections, changes in the number of pe-
ripheral IFN-γ-producing T cells specific for T. cruzi 
have been documented after BZ treatment (Laucella et al. 
2009). Other studies have found a relatively high expres-
sion of IFN-γ in the plasma or serum of patients with Cha-
gas cardiomyopathy compared to those with a noncardiac 
or indeterminate form of Chagas disease (Poveda et al. 
2014, Sousa et al. 2014). These results suggest a poten-
tial use for this cytokine as a biomarker of treatment out-
come. IL-10 is a major cytokine that modulates Th2 im-
mune responses. It is produced by monocytes and T cells 
and possesses antiinflammatory and immunoregulatory 
actions (Moore et al. 2001). IL-10 has been suggested to 
be crucial for the control of T. cruzi infection because IL-
10-deficient mice infected with T. cruzi showed a higher 
mortality rate compared to wild type infected animals 
(Abrahamsohn & Coffman 1996, Hunter et al. 1997). In 
humans, the association between high expression levels 
of IL-10 in serum and T. cruzi infected individuals dis-
playing better cardiac function has been reported (Sousa 
et al. 2014), suggesting that the study of this cytokine 
and its expression profiles in T. cruzi-infected individu-
als before and after treatment would be useful. IL-17 is 
the central component of the Th17 immune response. 
IL-17 functions as a proinflammatory cytokine that re-
sponds to the invasion of the immune system and induces 
the destruction of the pathogen’s cellular matrix (Kolls 
& Lindén 2004). Recent studies have shown that IL-17 
plays a protective role in experimental T. cruzi infection 
as well as in human Chagas disease (Miyazaki et al. 2010, 
Magalhães et al. 2013). As observed with IL-10, high ex-
pression levels of IL-17 were correlated with better cardi-
ac function (Costa et al. 2009, Magalhães et al. 2013). The 
potential use of changes in IL-17 as a surrogate marker of 
parasitological cure has not yet been explored.
Chemokines are key players in the control of the mi-
gration of specific cell types bearing their receptors to 
sites of tissue inflammation (Le et al. 2004). Monocyte 
chemotactic protein (MCP)-1 (or CCL2) is a small cy-
tokine that belongs to the CC chemokine family. CCL2 
recruits monocytes, memory T cells and dendritic cells to 
the sites of inflammation produced by either tissue injury 
or infection (Carr et al. 1994). A previous work found that 
CCL2/MCP-1 played a substantial role in controlling par-
asite burden, cell infiltration and mononuclear activation 
during acute T. cruzi infection (Paiva et al. 2009). CCL2/
MCP-1 has been suggested as a marker of prognostic val-
ue in other cardiovascular diseases (Tuñón et al. 2014).
Another chemokine known as macrophage inflam-
matory protein (MIP)-1α (or CCL3) is involved in in-
flammation and the recruitment and activation of poly-
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morphonuclear leukocytes (Menten et al. 2002). MIP-1α/
CCL3 plays a substantial role in the control of T. cruzi 
infection (Roffê et al. 2010). Moreover, this chemokine 
has also been proposed as a marker for disease progres-
sion in a parasitic infection (Falcão et al. 2002). How-
ever, the potential value of MCP-1/CCL2 and MIP-1α/
CCL3 as indicative markers of treatment outcomes in T. 
cruzi infection has not yet been studied.
The simultaneous detection of antibodies specific to 
the three evolutive forms of T. cruzi has recently been 
described (flow cytometric analysis of anti-live trypo-
mastigote and anti-fixed epimastigote antibodies). An-
tibodies directed against live amastigotes (AMA), live 
trypomastigotes (TRYPO) and fixed epimastigotes (EPI) 
were found in 100% of individuals with T. cruzi infection 
using differential fluorescence staining; moreover, the 6% 
of false positives detected in healthy individuals were at-
tributed to samples collected from leishmaniasis patients. 
The applicability of this technique in the post-therapeutic 
monitoring of Chagas disease has also been tested; 100% 
of nontreated and treated noncured samples tested posi-
tive against the three T. cruzi evolutive forms, while 100% 
of samples collected from the treated cured patients were 
negative against AMA, 93% were negative against TRYPO 
and 96% were negative against EPI (Alessio et al. 2014).
Other host biomarkers - Several inflammatory me-
diators have been proposed as biomarkers of the progres-
sion and/or response to treatment in patients with chron-
ic Chagas disease. Some of these markers have been 
proposed to identify early cardiac, gastrointestinal or 
potential neurological damage. Markers of cardiac dam-
age have been the most studied among the biomarkers of 
progression and some have been proposed as biomarkers 
of response to treatment.
Specific cardiological markers, such as troponin 
I and T and natriuretic peptides [i.e., atrial natriuretic 
peptide, brain natriuretic peptide (BNP) and N-terminal 
proBNP], have been proposed to determine disease pro-
gression when myocardial involvement was assessed 
both in the early (Puyó et al. 2002, 2005, Ribeiro et al. 
2003, Heringer-Walther et al. 2005, Moreira et al. 2008, 
García-Alvarez et al. 2010, Lima-Costa et al. 2010) and 
late (Puyó et al. 2002, Heringer-Walther et al. 2005, 
Machado et al. 2005) stages of the disease.
Biochemical molecules, such as glutamic oxaloacetic 
transaminase, glutamic-pyruvic transaminase, alkaline 
phosphatase, acid maltase, alpha-hydroxybutyric dehy-
drogenase (or LDH1), leptin, adipokines and angiotensin-
converting enzyme, have also been tested in humans to 
assess early cardiological damage (Alarcon-Corredor et 
al. 2002, Combs et al. 2005, Fernandes et al. 2007, Wang 
et al. 2010). Nevertheless, there are no reports of studies 
using these biomarkers to assess therapeutic efficacy.
Selenium levels have been studied as a progression 
marker for chronic digestive and cardiac manifestations, 
but have not been tested as a progression biomarker (Ri-
vera et al. 2002). Other molecules and enzyme systems, 
including caveolin-3, myocardial and peripheral pro-
tein-3-nitrotyrosine and its protein carbonyl formation, 
catalase, glutathione peroxidase, glutathione reductase, 
glutathione and Mn(2+) superoxide dismutase, have been 
reported to exhibit alterations in their regular function 
and/or expression in T. cruzi-infected animals. (Wen et 
al. 2004, Dhiman et al. 2008, Adesse et al. 2010)
Recently, some APO and several of their fragments 
[mature human APOA1 (28.1 kDa), fragments of hu-
man APOA1 (24.7, 13.6 and 9.3 kDa)] and a fragment 
of human fibronectin FN1 (28.9 kDa) were demonstrat-
ed to be useful for assessing the response to treatment 
with NFX in patients with chronic Chagas disease by 
surface-enhanced laser desorption/ionization analysis 
(Ndao 2012). The levels of these biomarkers in blood 
samples obtained three years after NFX treatment re-
turned to levels similar to those seen in healthy controls 
and the pattern of these biomarkers between healthy and 
diseased samples was consistent with those observed 
in our previous study. The sensitivity of this group of 
biomarkers was 89-100% and the specificity was up to 
98% (Santamaria et al. 2014). Overall, further studies 
are needed to correlate these changes with serological 
negativisation and seriated negative PCRs.
Other groups of potentially useful biomarkers in-
clude the hypercoagulability factors prothrombin frag-
ments 1+2 (F 1+2) and endogenous thrombin potential 
(ETP). Despite the large number of hypercoagulability 
biomarkers that have been tested in patients with T. cruzi 
infection in different stages, only one study tested these 
biomarkers after specific treatment with BZ (Pinazo 
et al. 2011). ETP and F 1+2 showed altered levels in T. 
cruzi-infected patients compared with controls (73% and 
80% of patients, respectively); these levels decreased 
significantly six months after treatment (100% and 73%, 
respectively). The evaluation of ETP and F 1+2 was con-
ducted in a nonendemic area for all stages of CD, thereby 
controlling for possible reinfection.
One of the advantages of hypercoagulability bio-
markers compared with the rest of the molecules and 
techniques described in other sections of this paper is 
that they are easily accessible at a reasonable cost in 
laboratories around the world because they represent 
regular tests performed in health care centres’ labora-
tories. Most of them do not require an expert technician 
and highly technological equipment. However, the two 
groups that have shown the most potential usefulness 
after treatment were recently tested and presented some 
limitations. Further studies will be required to validate 
their use in diagnosis or prognosis.
Concluding remarks
There are currently several groups of biomarkers that 
have exhibited potential usefulness for the assessment of 
responses to specific T. cruzi treatments; these biomark-
ers are related to the parasite itself or the host response 
to the parasite presence. The research on parasite bio-
markers is currently more developed than the research 
on host response biomarkers. Among parasite biomark-
ers, nucleic acid amplification techniques are the most 
common and have demonstrated their effectiveness in 
assessing therapeutic failure and cure after specific 
treatments in several experiments.
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Several studies concerning immunological and bio-
chemical markers related to the host response to the 
parasite have been recently published, but further stud-
ies must be performed to determine their usefulness in 
different clinical and epidemiological settings.
The availability of different types of new biomark-
ers combined with standardised criteria will be ex-
tremely useful in clinical trials involving the develop-
ment of new and improved drugs to properly treat this 
neglected tropical disease.
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